The 36-month beta value for CGTX is also noteworthy at 0.87. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CGTX is 50.00M, and at present, short sellers hold a 3.08% of that float. The average trading volume of CGTX on July 02, 2025 was 1.17M shares.
CGTX) stock’s latest price update
Cognition Therapeutics Inc (NASDAQ: CGTX) has seen a rise in its stock price by 8.81% in relation to its previous close of $0.31. However, the company has experienced a 13.27% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
CGTX’s Market Performance
Cognition Therapeutics Inc (CGTX) has seen a 13.27% rise in stock performance for the week, with a 7.19% gain in the past month and a -13.34% plunge in the past quarter. The volatility ratio for the week is 9.18%, and the volatility levels for the past 30 days are at 11.74% for CGTX. The simple moving average for the past 20 days is 12.97% for CGTX’s stock, with a -28.30% simple moving average for the past 200 days.
Analysts’ Opinion of CGTX
Many brokerage firms have already submitted their reports for CGTX stocks, with B. Riley Securities repeating the rating for CGTX by listing it as a “Buy.” The predicted price for CGTX in the upcoming period, according to B. Riley Securities is $1.50 based on the research report published on December 19, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to CGTX, setting the target price at $22 in the report published on November 03rd of the previous year.
CGTX Trading at 3.07% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.60% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 38,851 shares at the price of $0.77 back on Jan 31 ’25. After this action, Ricciardi Lisa now owns 38,851 shares of Cognition Therapeutics Inc, valued at $30,001 using the latest closing price.
Stock Fundamentals for CGTX
The total capital return value is set at -4.27. Equity return is now at value -161.93, with -106.81 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -65.63. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -5363.9.
Currently, EBITDA for the company is -33.68 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.
Conclusion
In summary, Cognition Therapeutics Inc (CGTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
